HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Diphenylhexatriene

A fluorescent compound that emits light only in specific configurations in certain lipid media. It is used as a tool in the study of membrane lipids.
Also Known As:
1,6-Diphenyl-1,3,5-hexatriene; 1,6-Diphenylhexatriene; 1,6 Diphenylhexatriene; Benzene, 1,1'-(1,3,5-hexatriene-1,6-diyl)bis-
Networked: 67 relevant articles (0 outcomes, 7 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Jang, Jin Ho: 1 article (04/2018)
2. Kim, Jong-Sang: 1 article (04/2018)
3. Kim, Jungeun: 1 article (04/2018)
4. Kim, Woo-Keun: 1 article (04/2018)
5. Lee, Sangwoo: 1 article (04/2018)
6. Oh, Jisun: 1 article (04/2018)
7. Park, Chul Min: 1 article (04/2018)
8. Saini, Manpreet Kaur: 1 article (06/2014)
9. Sanyal, Sankar Nath: 1 article (06/2014)
10. Cordeiro-da-Silva, Anabela: 1 article (08/2008)

Related Diseases

1. Neoplasms (Cancer)
2. Alzheimer Disease (Alzheimer's Disease)
07/01/1999 - "Previous fluorescence studies employing 1,6-diphenyl-1,3,5-hexatriene (DPH) have revealed an increase in the fluidity of platelet membranes from individuals with Alzheimer's disease (AD) and their first-degree relatives. "
03/01/1992 - "To test whether increased platelet membrane fluidity as measured by decreased steady state fluorescence anisotropy (rs) of diphenylhexatriene is a biologic/diagnostic marker for Alzheimer's disease (AD), we enrolled 95 clinically diagnosed, probable AD cases from our Alzheimer's Disease Patient Registry and 133 control subjects of similar age and sex randomly selected from the same population base as the cases. "
01/01/1990 - "Increased platelet membrane fluidity, as determined by the fluorescence anisotropy of 1,6-diphenyl-1,3,5-hexatriene (DPH), appears to be a stable, inherited trait that identifies a prominent subgroup of patients with Alzheimer's disease with distinct clinical features. "
06/01/1989 - "The fluorescence anisotropy of 1,6-diphenyl-1,3,5-hexatriene in labeled platelet membranes, an index of membrane fluidity, is a stable, familial trait that is associated with a clinically distinct subtype of Alzheimer disease. "
12/01/1988 - "Increased platelet membrane fluidity, as reflected by a decrease in the fluorescence anisotropy of diphenylhexatriene in labeled membranes, identifies a clinically distinct subgroup of approximately 50% of patients at our center who meet NINCDS-ADRDA clinical criteria for Alzheimer's disease. "
3. Vesicular Stomatitis
4. Melanoma (Melanoma, Malignant)
5. Rheumatoid Arthritis

Related Drugs and Biologics

1. Lipids
2. Fluorescent Dyes (Fluorescent Probes)
3. Membrane Lipids
4. Liposomes (Liposome)
5. Doxorubicin (Adriamycin)
6. pyrene
7. 1- (4- (trimethylamino)phenyl)- 6- phenylhexa- 1,3,5- triene
8. Hemoglobins (Hemoglobin)
9. Antirheumatic Agents (DMARD)
10. Sodium

Related Therapies and Procedures

1. Aftercare (After-Treatment)